Myelodysplastic syndrome (MDS) with del(5q) constitutes a distinct subtype of MDS associated with a favorable prognosis and a relatively low risk of leukemic transformation. 1 Lenalidomide, a thalidomide analog with immunomodulatory and anti-angiogenic properties, induced transfusion independence and cytogenetic response in a high proportion of MDS patients with del(5q). 2 Thus, treatment with lenalidomide provides a new important therapeutic option for patients with transfusiondependent anemia. Yet, most patients relapsed after a median of 2 years of treatment and one third of these patients progressed to acute myeloid leukemia. As most of these patients developed complex aberrant karyotypes, genetic instability and clonal evolution seem to be a driving force for the leukemic transformation. 3 The mechanisms inducing clonal evolution in MDS patients with del(5q) following the lenalidomide treatment remain obscure. However, small subclones with TP53 mutations were recently identified as a risk factor for leukemic transformation in low-risk del(5q) MDS, if these are primary or secondary events remain to be clarified. 4 Further identification of predictive markers identifying patients with increased risk of disease progression would greatly improve patient care.
We reasoned that telomere shortening may be involved in clonal evolution and acute myeloid leukemia progression. Telomeres consist of TTAGGG repeats, which form a specialized nucleoprotein structure ('T-loop') that caps the chromosome ends. Telomere length is about 15 kb in the fetus and decreases with each cell division during the organism's lifetime due to the end-replication problem. 5 Thus, telomeres eventually reach a critically short length as a natural consequence of aging or due to increased proliferative stress. These short telomeres lose their ability to protect the chromosome ends and appear as DNA double-strand breaks, which induce DNA damage responses and breakage-fusion-bridge cycles that result in increased chromosomal instability and chromosomal aberrations. The cells will thus undergo apoptosis unless mutations, for example, of TP53, enable the apoptosis to be bypassed or telomeres are elongated by telomerase or alternative lengthening of telomeres. Telomere shortening has an important role in the pathogenesis of MDS and other malignancies. 6 To better decipher the mechanisms responsible for disease progression in MDS patients with del(5q), we performed a casecontrol study using T/C-FISH (telomere/centromere-fluorescence in-situ hybridization) for telomere length measurement in combination with fluorescence R-banding analyses. The study aimed to compare telomere lengths from bone marrow cultures (representing myeloid progenitor cells) at an early time point after initial diagnosis and before lenalidomide treatment with telomere lengths determined during follow-up.
This study included 14 patients with transfusion-dependent anemia due to low-or intermediate 1-risk MDS (according to the International prognostic scoring system (IPSS)) associated with del(5q) with or without additional cytogenetic abnormalities. Seven patients (study group) underwent disease progression after a median of 29.1 months, and seven patients (control group) had continuous hematologic and cytogenetic remission or stable disease ( Table 1 ). The study group and the control group neither differ in disease history,age or other relevant clinical parameters like marrow blast count, hemoglobin, neutrophils and thrombocytes, nor in the presence of additional aberrations (Supplementary Tables S1-S4) . Detailed information about methods and statistical analyses (Supplementary Materials and Methods) can be retrieved from Supplementary Information.
At study entry, five of seven patients with and six of seven patients without disease progression had an isolated del(5q). Additional aberrations, that is, inv(3)(q13q25) not involving EVI1, del(12)(p12p13) and an unbalanced t(1;2), were observed in three patients (Table 1) . Three patients with disease progression, two of them (patients 4 and 5) after achieving a complete cytogenetic remission, developed a complex karyotype with typical aberrations like monosomy 7, trisomy 8 or loss of 17p including the TP53 locus. Clonal evolution occurred within 22-51 months (patients 4, 5 and 6).
Before lenalidomide treatment, patients who subsequently underwent disease progression had a median telomere length of 6.1 kb (range 4.8-7.9 kb). In contrast, patients who did not later undergo disease progression had a median telomere length of 9.3 kb (range 8.4-10.2) (Table 1; Figure 1 ; Supplementary Tables S3  and S4 ). Importantly, telomere length in patients who did not progress was similar to age-and gender-matched healthy controls from our previous study (9.5 kb, range 8.0-12.0 kb) 7 and according to the study of Mayer et al.
5 (8.3 kb) . Thus, patients without later progression showed normal telomere lengths.
Telomere length was determined in cells containing a del(5q). Before treatment, the clone with del(5q) had significantly shorter telomeres in patients with subsequent disease progression than in those with continuous cytogenetic remission or stable disease (Po0.001).
In the cohort of patients with subsequent disease progression, patients with an isolated del(5q) (n ¼ 5) and patients with additional aberrations (n ¼ 2) had similar telomere lengths (5.9 kb and 6.8 kb, respectively).
Four of seven patients (patients 1, 2, 3 and 7) who underwent disease progression showed no karyotypic evolution. However, their median telomere length did not differ from that of the three patients (patients 4, 5 and 6) who developed a complex karyotype during progression (6.0 kb and 6.4 kb, respectively). Although confirmation in larger patient cohorts and agematched controls is needed, telomere length below a cutoff level of 8 kb, calculated by a receiver operating characteristic function, seems to predict an increased risk for disease progression.
To identify potential changes in telomere length, measurements were repeated at later time points in six of seven patients from both cohorts ( Table 1; Supplementary Tables S3 and S4) . Notably, telomere length in patients with a subsequent disease progression increased significantly during lenalidomide treatment (Po0.02). During 5-51 months of treatment (median 29.1 months) median telomere length increased from 6.1 to 8.5 kb. Thus, the median increase in length was 2.4 kb (range 0.5-3.4 kb). When material was available, telomere length was also measured at additional time points (two of seven patients). In these two cases, it was possible to detect continuous telomere elongation during lenalidomide treatment, with the longest telomeres measured at the latest treatment time point. The telomere length of patient 2 increased from 5.7 to 6.4 kb within 16 months and reached 8.7 kb after 38 months of treatment. Similarly, telomeres of patient 3, which were initially 4.8 kb long, increased to 7.3 kb after 13 months and reached a length of 8.2 kb after 25 months of lenalidomide treatment.
In contrast, patients who did not undergo disease progression showed no relevant telomere elongation or shortening (P40.05) with 9.3 kb at study entry and 8.8 kb at later time points after 11-52 months (median 28.3 months) of lenalidomide treatment. The median change was 0.5 kb (range À0.7 kb to þ 0.9).
In two patients (patients 3 and 6), we were able to compare telomere length in normal and aberrant metaphases 13 and 29 months after lenalidomide treatment. Patient 3 had a mosaic of an isolated del(5q) and a normal karyotype. Patient 6 had a mosaic of a complex and a normal karyotype. While telomere lengths increased in the aberrant cells from both patients, telomeres of normal bone marrow cells remained longer than telomeres of aberrant cells (9.1 and 9.7 kb for normal cells compared with 6.9 and 5.5 kb for the aberrant cells, respectively). Further analyses in other patients were not possible due to a lack of material.
Cells with excessively shortened telomeres may undergo repeated fusion-bridge-fusion cycles that lead to an accumulation of chromosomal aberrations and aneuploidy. Chromosomal aberrations, which provide a proliferative advantage, may promote cell survival and select for outgrowth of leukemic clones. In later stages, aberrations can be stabilized by activating telomerase or other telomere-elongating mechanisms like the alternative lengthening of telomeres (ALT) mechanism. In line with this hypothesis, three patients from this study with very short telomeres (4.8 kb, 6.4 kb and 7.9 kb, respectively) underwent karyotypic evolution and developed complex karyotypes. Due to insufficient amounts of material, we were not able to investigate whether telomerase or alternative lengthening of telomeres was activated in patients with critically short telomeres (for example, o8 kb) during clonal evolution or disease progression. Alternatively, this may be due to clonal selection. If the majority of myeloid progenitors with critically short telomeres are eliminated and stem cells with del(5q) and longer telomeres survive and proliferate, this may appear to be telomere elongation. Indeed, functionally defined del(5q) stem cells remained distinctly resistant to lenalidomide. 8 Our results from two patients may indicate that telomere shortening occurred preferentially in the aberrant cells. While the underlying mechanisms leading to excessive telomere length shortening in MDS with del(5q) remain unclear, telomere length measurement may in the future provide a diagnostic tool for predicting treatment response and disease outcome after lenalidomide treatment.
In summary, we were able to investigate telomere dynamics in MDS patients with del(5q) during lenalidomide treatment. Before lenalidomide treatment, patients who later underwent leukemic transformation had significantly shorter telomeres than patients who had a continuous cytogenetic remission or stable disease. Thus, telomere shortening may be predictive of an increased risk for leukemic transformation. Clearly, these data require confirmation in larger patient cohorts. Letters to the Editor
